Skip to main content
Top

25-01-2025 | Type 2 Diabetes | Review Article

Serum adipsin levels as a new marker in type 2 diabetes mellitus: A meta-analysis

Authors: Abhishek Bansal, Vaishali Kolgiri Honnapurmath, Alka Singh

Published in: International Journal of Diabetes in Developing Countries

Login to get access

Abstract

Background

Type 2 diabetes mellitus (T2DM) is a global health concern characterized by insulin resistance and impaired insulin secretion. Traditional markers have limitations in early detection. Adipsin, an adipokine involved in insulin secretion and β-cell function, may serve as a novel biomarker for T2DM diagnosis.

Objective

This meta-analysis evaluates serum adipsin levels in individuals with T2DM to assess its potential as a biomarker.

Methods

A systematic search was conducted in PubMed, including observational studies, cohort, and cross-sectional studies. Data extraction was done independently by two reviewers, and pooled analysis was performed using a random-effects model. Mean differences in serum adipsin levels between T2DM patients and controls were calculated.

Results

Eight studies were included in our study. The pooled mean serum adipsin level in T2DM patients was 3.44 ng/mL (95% CI 2.72–4.15), significantly lower than in controls 6.01 ng/mL (95% CI 4.26–7.75, p = 0.01) with mean difference − 2.47 ng/mL (95% CI − 4.49 to − 0.45). Heterogeneity was high across studies (I2 = 85.61% for T2DM, I2 = 94.3% for controls).

Conclusion

The results show significantly lower serum adipsin levels in T2DM patients, supporting its promising, biomarker. Reduced adipsin levels may contribute to T2DM pathophysiology by affecting insulin regulation and glucose metabolism. Serum adipsin is a promising biomarker for T2DM diagnosis. Further research is needed to explore its clinical utility and therapeutic potential in managing T2DM.
Literature
1.
go back to reference Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et al. Diabetes mellitus: Classification, mediators, and complications; a gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023;168:115734.CrossRefPubMed Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et al. Diabetes mellitus: Classification, mediators, and complications; a gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023;168:115734.CrossRefPubMed
2.
go back to reference Husein R, Depkes RI, Soelistijo SA, Novida H, Rudijanto A, BPJS, et al. Classification of diabetes mellitus. Department for Management of NCD, Disability, Violence and Injury Prevention. 2018;138(9):271–81. Husein R, Depkes RI, Soelistijo SA, Novida H, Rudijanto A, BPJS, et al. Classification of diabetes mellitus. Department for Management of NCD, Disability, Violence and Injury Prevention. 2018;138(9):271–81.
3.
go back to reference Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):1–34.CrossRef Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):1–34.CrossRef
4.
go back to reference Geor RJ. Endocrine and metabolic physiology. Equine Applied and Clinical Nutrition: Health, Welfare and Performance. 2013;1:33–63. Geor RJ. Endocrine and metabolic physiology. Equine Applied and Clinical Nutrition: Health, Welfare and Performance. 2013;1:33–63.
6.
7.
go back to reference Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62.CrossRef Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62.CrossRef
8.
go back to reference Jha BK, Sherpa ML, Imran M, Mohammed Y, Jha LA, Paudel KR, et al. Progress in understanding metabolic syndrome and knowledge of its complex pathophysiology. Diabetology. 2023;4(2):134–59.CrossRef Jha BK, Sherpa ML, Imran M, Mohammed Y, Jha LA, Paudel KR, et al. Progress in understanding metabolic syndrome and knowledge of its complex pathophysiology. Diabetology. 2023;4(2):134–59.CrossRef
9.
go back to reference Bogdanet D, Reddin C, Murphy D, Doheny HC, Halperin JA, Dunne F, et al. Emerging protein biomarkers for the diagnosis or prediction of gestational diabetes—a scoping review. J Clin Med. 2021;10(7):1533.CrossRefPubMedPubMedCentral Bogdanet D, Reddin C, Murphy D, Doheny HC, Halperin JA, Dunne F, et al. Emerging protein biomarkers for the diagnosis or prediction of gestational diabetes—a scoping review. J Clin Med. 2021;10(7):1533.CrossRefPubMedPubMedCentral
10.
go back to reference Yau M, Maclaren NK, Sperling MA. Etiology and pathogenesis of diabetes mellitus in children and adolescents. Endotext [Internet]. 2021. Yau M, Maclaren NK, Sperling MA. Etiology and pathogenesis of diabetes mellitus in children and adolescents. Endotext [Internet]. 2021.
11.
go back to reference Ortiz-Martínez M, González-González M, Martagón AJ, Hlavinka V, Willson RC, Rito-Palomares M. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. Curr Diab Rep. 2022;22(3):95.CrossRefPubMedPubMedCentral Ortiz-Martínez M, González-González M, Martagón AJ, Hlavinka V, Willson RC, Rito-Palomares M. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. Curr Diab Rep. 2022;22(3):95.CrossRefPubMedPubMedCentral
12.
go back to reference Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The role of adipokines in inflammatory mechanisms of obesity. Int J Mol Sci. 2022;23(23):14982.CrossRefPubMedPubMedCentral Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The role of adipokines in inflammatory mechanisms of obesity. Int J Mol Sci. 2022;23(23):14982.CrossRefPubMedPubMedCentral
13.
go back to reference Brunton PJ, Russell JA. Maternal brain adaptations in pregnancy. Knobil and Neill’s Physiology of Reproduction: Two-Volume Set. 2015;2:1957–2026. Brunton PJ, Russell JA. Maternal brain adaptations in pregnancy. Knobil and Neill’s Physiology of Reproduction: Two-Volume Set. 2015;2:1957–2026.
14.
go back to reference Blüher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab. 2013;27(2):163–77.CrossRefPubMed Blüher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab. 2013;27(2):163–77.CrossRefPubMed
15.
go back to reference Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Martín-Rodríguez A, Martínez-Guardado I, Navarro-Jiménez E, et al. The role of adipokines in health and disease. Biomedicines. 2023;11(5):1290.CrossRefPubMedPubMedCentral Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Martín-Rodríguez A, Martínez-Guardado I, Navarro-Jiménez E, et al. The role of adipokines in health and disease. Biomedicines. 2023;11(5):1290.CrossRefPubMedPubMedCentral
17.
go back to reference Tafere GG, Wondafrash DZ, Zewdie KA, Assefa BT, Ayza MA. Plasma adipsin as a biomarker and its implication in type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2020;13:1855.CrossRefPubMedPubMedCentral Tafere GG, Wondafrash DZ, Zewdie KA, Assefa BT, Ayza MA. Plasma adipsin as a biomarker and its implication in type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2020;13:1855.CrossRefPubMedPubMedCentral
18.
go back to reference Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–56.CrossRefPubMed Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–56.CrossRefPubMed
19.
go back to reference Poveda NE, Garcés MF, Ruiz-Linares CE, Varón D, Valderrama S, Sanchez E, et al. Serum adipsin levels throughout normal pregnancy and preeclampsia. Sci Rep. 2016;6(1):1–11.CrossRef Poveda NE, Garcés MF, Ruiz-Linares CE, Varón D, Valderrama S, Sanchez E, et al. Serum adipsin levels throughout normal pregnancy and preeclampsia. Sci Rep. 2016;6(1):1–11.CrossRef
21.
go back to reference Byeon HJ, Chae MK, Ko JS, Lee EJ, Kikkawa DO, Jang SY, et al. The role of adipsin, complement factor d, in the pathogenesis of graves’ orbitopathy. Invest Ophthalmol Vis Sci. 2023;64(11):13–13.CrossRefPubMedPubMedCentral Byeon HJ, Chae MK, Ko JS, Lee EJ, Kikkawa DO, Jang SY, et al. The role of adipsin, complement factor d, in the pathogenesis of graves’ orbitopathy. Invest Ophthalmol Vis Sci. 2023;64(11):13–13.CrossRefPubMedPubMedCentral
22.
go back to reference Corvillo F, González-Sánchez L, López-Lera A, Arjona E, Ceccarini G, Santini F, et al. Complement factor D (adipsin) levels are elevated in acquired partial lipodystrophy (Barraquer–Simons syndrome). Int J Mol Sci. 2021;22(12):6608.CrossRefPubMedPubMedCentral Corvillo F, González-Sánchez L, López-Lera A, Arjona E, Ceccarini G, Santini F, et al. Complement factor D (adipsin) levels are elevated in acquired partial lipodystrophy (Barraquer–Simons syndrome). Int J Mol Sci. 2021;22(12):6608.CrossRefPubMedPubMedCentral
24.
go back to reference Barratt J, Weitz I. Complement factor D as a strategic target for regulating the alternative complement pathway. Front Immunol. 2021;9:12. Barratt J, Weitz I. Complement factor D as a strategic target for regulating the alternative complement pathway. Front Immunol. 2021;9:12.
25.
go back to reference Tangjittipokin W, Thanatummatis B, Wardati F, Narkdontri T, Teerawattanapong N, Boriboonhirunsarn D. The genetic polymorphisms and levels of adipokines and adipocytokines that influence the risk of developing gestational diabetes mellitus in Thai pregnant women. Gene. 2023;15:860. Tangjittipokin W, Thanatummatis B, Wardati F, Narkdontri T, Teerawattanapong N, Boriboonhirunsarn D. The genetic polymorphisms and levels of adipokines and adipocytokines that influence the risk of developing gestational diabetes mellitus in Thai pregnant women. Gene. 2023;15:860.
26.
go back to reference Raoof EMM, Ahmed HS. Circulating adipsin as biomarker and its implication in type 2 diabetes mellitus. Int J Drug Deliv Technol. 2022;12(2):588–93. Raoof EMM, Ahmed HS. Circulating adipsin as biomarker and its implication in type 2 diabetes mellitus. Int J Drug Deliv Technol. 2022;12(2):588–93.
27.
go back to reference Farhan LO, Abed BA, Dawood A. Baghdad Science Journal Comparison Study between Adipsin Levels in Sera of Iraqi Patients with Diabetes and Neuropathy. Baghdad Sci J. 2023;20:0726.CrossRef Farhan LO, Abed BA, Dawood A. Baghdad Science Journal Comparison Study between Adipsin Levels in Sera of Iraqi Patients with Diabetes and Neuropathy. Baghdad Sci J. 2023;20:0726.CrossRef
29.
go back to reference Wang JS, Lee WJ, Te LI, Lin SY, Lee WL, Liang KW, et al. Association between serum adipsin levels and insulin resistance in subjects with various degrees of glucose intolerance. J Endocr Soc. 2018;3(2):403–10.CrossRefPubMedPubMedCentral Wang JS, Lee WJ, Te LI, Lin SY, Lee WL, Liang KW, et al. Association between serum adipsin levels and insulin resistance in subjects with various degrees of glucose intolerance. J Endocr Soc. 2018;3(2):403–10.CrossRefPubMedPubMedCentral
30.
go back to reference Karajibani M, Montazerifar F, Sadeghi MB, Keikhaie MA, Dashipour A. Serum fetuin-A and adipsin levels in type ii diabetes patients. Int J High Risk Behav Addict. 2019;8(3):91963.CrossRef Karajibani M, Montazerifar F, Sadeghi MB, Keikhaie MA, Dashipour A. Serum fetuin-A and adipsin levels in type ii diabetes patients. Int J High Risk Behav Addict. 2019;8(3):91963.CrossRef
31.
go back to reference Zhou Q, Ge Q, Ding Y, Qu H, Wei H, Wu R, et al. Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance. J Diabetes Investig. 2018;9(5):1128–34.CrossRefPubMedPubMedCentral Zhou Q, Ge Q, Ding Y, Qu H, Wei H, Wu R, et al. Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance. J Diabetes Investig. 2018;9(5):1128–34.CrossRefPubMedPubMedCentral
34.
go back to reference Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158(1):41.CrossRefPubMedPubMedCentral Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158(1):41.CrossRefPubMedPubMedCentral
36.
go back to reference Tangjittipokin W, Narkdontri T, Teerawattanapong N, Thanatummatis B, Wardati F, Sunsaneevithayakul P, et al. The variants in ADIPOQ are associated with maternal circulating adipokine profile in gestational diabetes mellitus. J Multidiscip Healthc. 2023;16:309–19.CrossRefPubMedPubMedCentral Tangjittipokin W, Narkdontri T, Teerawattanapong N, Thanatummatis B, Wardati F, Sunsaneevithayakul P, et al. The variants in ADIPOQ are associated with maternal circulating adipokine profile in gestational diabetes mellitus. J Multidiscip Healthc. 2023;16:309–19.CrossRefPubMedPubMedCentral
37.
go back to reference Legakis I, Mantzouridis T, Bouboulis G, Chrousos GP. Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast. Arch Endocrinol Metab. 2016;60(1):76–8.CrossRefPubMedPubMedCentral Legakis I, Mantzouridis T, Bouboulis G, Chrousos GP. Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast. Arch Endocrinol Metab. 2016;60(1):76–8.CrossRefPubMedPubMedCentral
38.
go back to reference Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS ONE. 2014;9(3):e91969.CrossRefPubMedPubMedCentral Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS ONE. 2014;9(3):e91969.CrossRefPubMedPubMedCentral
39.
go back to reference Plante E, Menaouar A, Danalache BA, Yip D, Broderick TL, Chiasson JL, et al. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice. Endocrinology (United States). 2015;156(4):1416–28. Plante E, Menaouar A, Danalache BA, Yip D, Broderick TL, Chiasson JL, et al. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice. Endocrinology (United States). 2015;156(4):1416–28.
40.
go back to reference Milek M, Moulla Y, Kern M, Stroh C, Dietrich A, Schön MR, et al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int J Mol Sci. 2022;23(4):2222.CrossRefPubMedPubMedCentral Milek M, Moulla Y, Kern M, Stroh C, Dietrich A, Schön MR, et al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int J Mol Sci. 2022;23(4):2222.CrossRefPubMedPubMedCentral
41.
go back to reference Singh S, Hussain S, Yadav SS, Tiwari NP, Usman K, Sawlani KK, et al. Association of serum adipsin level with insulin resistance and inflammatory markers in newly diagnosed type two diabetes mellitus patients. Indian J Clin Biochem. 2024;39(3):415–20.CrossRefPubMed Singh S, Hussain S, Yadav SS, Tiwari NP, Usman K, Sawlani KK, et al. Association of serum adipsin level with insulin resistance and inflammatory markers in newly diagnosed type two diabetes mellitus patients. Indian J Clin Biochem. 2024;39(3):415–20.CrossRefPubMed
42.
go back to reference Hase K, Kanda A, Hirose I, Noda K, Ishida S. Systemic factors related to soluble (pro)renin receptor in plasma of patients with proliferative diabetic retinopathy. PLoS ONE. 2017;12(12):e0189696.CrossRefPubMedPubMedCentral Hase K, Kanda A, Hirose I, Noda K, Ishida S. Systemic factors related to soluble (pro)renin receptor in plasma of patients with proliferative diabetic retinopathy. PLoS ONE. 2017;12(12):e0189696.CrossRefPubMedPubMedCentral
43.
go back to reference Ruscitti P, Ursini F, Cipriani P, Greco M, Alvaro S, Vasiliki L, et al. IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: an observational study. Medicine (United States). 2019;98(7):e14587. Ruscitti P, Ursini F, Cipriani P, Greco M, Alvaro S, Vasiliki L, et al. IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: an observational study. Medicine (United States). 2019;98(7):e14587.
Metadata
Title
Serum adipsin levels as a new marker in type 2 diabetes mellitus: A meta-analysis
Authors
Abhishek Bansal
Vaishali Kolgiri Honnapurmath
Alka Singh
Publication date
25-01-2025
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-025-01449-2

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more